11250 EL CAMINO REAL, SUITE 100, SAN DIEGO, CA
Material disclosure
Skye Bioscience Enters Material Definitive Agreement with Redmile Group
Amended material disclosure
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Announce Transaction Agreement and $125 Million in Financings, Investor Presentation
Other Events
Skye Bioscience Increases Authorized Shares to 300 Million
Annual Report to Security Holders
Q2
Q1
FY 2025
Q3
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
PREM14A
Submission Upload
Correspondence